Final Project Ideas
FINAL PROJECT IDEAS
GXM UPTAKE INHIBITOR (s.neoformans, c.gatti)
EARLY LIVER DAMAGE BIOSENSOR
BIOSENSOR FOR TOXICOLOGY
GXM UPTAKE INHIBITOR (GXM SHIELD)
Concept: A dual-therapy approach using in silico designed proteins to Shield liver receptors and a non-Fc Sponge to neutralize and redirect GXM to renal clearance.
Aim 1: The Liver Shield (Receptor Antagonism)
Goal: Block the “portals” (CD14, SR-A1, TLR4) that capture GXM into the liver/spleen.
Step 1: Interface Mapping: Use AlphaFold 3 to map the hydrophobic pockets of human CD14 (residues 1–152) and the trimeric collagenous domain of SR-A1.
Step 2: Design: Generate small, high-affinity protein “plugs” that mimic GXM but lack its toxic signaling.
Step 3: Sequence Refinement: Use ProteinMPNN to ensure these binders are highly soluble and stable at physiological pH (7.4).
Primary Toolset: AlphaFold 3, RFdiffusion, ProteinMPNN, PyMOL (visualization).
Aim 2: The GXM Sponge (Non-Fc Sequestration)
Goal: Create a high-affinity “scavenger” protein that binds circulating GXM without triggering liver uptake.
- Step 1: Epitope Modeling: Model the M2 hexasaccharide motif of GXM (focusing on mannose backbone).
- Step 2: Binder Generation: Design a scaffold based on the known GXM-binding peptide sequence.
Primary Toolset: BindCraft, AlphaFold 3 (Carbohydrate module), Rosetta (stability testing).
Aim 3: Systems Modeling & Clearance Simulation
Goal: Quantify the therapeutic window and “redirection” efficiency.
- Step 1: Pharmacokinetic (PK) Modeling
- Step 2: Competitive Binding Simulation. Simulate the “Shield” occupying 90% of Kupffer cell receptors before the “Sponge” is released.
- Step 3: Clearance Prediction. Calculate the rate of Renal Clearance vs. Liver Accumulation for the Sponge-GXM complex.
Primary Toolset: PK-Sim, MATLAB (SimBiology), R (mrgsolve).
Experimental Validation (Wet Lab)
- Production: Synthesize the Aim 1 & 2 proteins via E. coli expression or mRNA-LNP delivery.
- Binding: Confirm the Sponge’s affinity for purified GXM.
- Competition: Perform a Flow Cytometry assay on human HepG2 or Kupffer cells to prove the Shield prevents GXM uptake.
- CD14 Structural Domains: Structural basis of CD14-Lipid Interaction
- AlphaFold 3 Capabilities: Isomorphic Labs Whitepaper
- GXM Sequestration Dynamics: The Casadevall Lab Papers
- https://pubs.rsc.org/en/content/articlelanding/2020/sc/d0sc01249a
- https://pmc.ncbi.nlm.nih.gov/articles/PMC1307074/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC1346664/#:~:text=There%20are%20several%20direct%20and,to%20the%20pathogenesis%20of%20cryptococcosis.